Adelene Q Perkins
CIK 1375124 · Chief Executive Officer · last filed 2026-02-18
Adelene Q Perkins is a Chief Executive Officer who has filed 53 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for BRKRP, was dated Feb 18, 2026. Across all open-market trades the lifetime net is −$1.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $13.8M across reported positions. 11 SEC filings were submitted jointly with BRUKER CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INFI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
780 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BRKRP | Director | 29,144 | $425.71 | $12.41M | $0 | 1 | 2026-02-18 |
| BRKR | Director | 24,624 | $58.23 | $1.43M | $0 | 9 | 2025-02-19 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Chief Executive Officer | 1,601,933 | $0.04 | $71.6K | -$1.63M | 43 | 2023-09-12 |
Recent Filings
53 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-18 | BRKRP | Grant (A) | +4,520 | $0 | EDGAR |
| 2025-02-19 | BRKR | Grant (A) | +3,298 | $0 | EDGAR |
| 2024-01-09 | BRKR | Grant (A) | +2,377 | $0 | EDGAR |
| 2023-09-12 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Mixed | +357,937 | -$28.7K | EDGAR |
| 2023-01-09 | BRKR | Grant (A) | +1,970 | $0 | EDGAR |
| 2022-01-12 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-06 | BRKR | Grant (A) | +1,841 | $0 | EDGAR |
| 2021-01-07 | BRKR | Grant (A) | +2,302 | $0 | EDGAR |
| 2020-12-23 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-01-13 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Grant (A) | +155,134 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.